GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults.

MLA

Lanini, Simone, et al. “GRAd-COV2, a Gorilla Adenovirus-Based Candidate Vaccine against COVID-19, Is Safe and Immunogenic in Younger and Older Adults.” Science Translational Medicine, vol. 14, no. 627, Jan. 2022, p. eabj1996. EBSCOhost, https://doi.org/10.1126/scitranslmed.abj1996.

APA

Lanini, S., Capone, S., Antinori, A., Milleri, S., Nicastri, E., Camerini, R., Agrati, C., Castilletti, C., Mori, F., Sacchi, A., Matusali, G., Gagliardini, R., Ammendola, V., Cimini, E., Grazioli, F., Scorzolini, L., Napolitano, F., Plazzi, M. M., Soriani, M., … Ippolito, G. (2022). GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. Science Translational Medicine, 14(627), eabj1996. https://doi.org/10.1126/scitranslmed.abj1996

Chicago

Lanini, Simone, Stefania Capone, Andrea Antinori, Stefano Milleri, Emanuele Nicastri, Roberto Camerini, Chiara Agrati, et al. 2022. “GRAd-COV2, a Gorilla Adenovirus-Based Candidate Vaccine against COVID-19, Is Safe and Immunogenic in Younger and Older Adults.” Science Translational Medicine 14 (627): eabj1996. doi:10.1126/scitranslmed.abj1996.